Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2779378 | 0.86 | LMNA (0.40) | PTGESHTTEPHX2NPC1TP53 | |
| SCHEMBL2809264 | 0.79 | EPHX2 (0.38) | PTGESHTTSIRT2EPHX2MAPT | |
| SCHEMBL2782126 | 0.78 | CNR2 (0.36) | — | |
| SCHEMBL2805095 | 0.77 | CNR2 (0.36) | — | |
| SCHEMBL185312 | 0.77 | TAS2R14 (0.42) | SIRT2EPHX2TP53TAS2R14 | |
| SCHEMBL12473674 | 0.76 | CNR2 (0.38) | TP53MAPTRAB9A | |
| SCHEMBL13159675 | 0.75 | EPHX2 (0.44) | EPHX2NPC1 | |
| SCHEMBL19418574 | 0.75 | EPHX2 (0.44) | EPHX2NPC1 | |
| SCHEMBL2810807 | 0.75 | PTGS2 (0.41) | SIRT2EPHX2NPC1HPGDTAS2R14 | |
| SCHEMBL2809267 | 0.74 | GAA (0.37) | PTGESSIRT2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539323-B3 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2017-10-04 | — | — | EP | disclosed |
| EP-2539323-B1 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2014-12-03 | — | — | EP | disclosed |
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-8372838-B2 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-12 | — | — | US | disclosed |
| US-20120142695-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142695-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | PTGES 763/4885HTT 2934/4885SIRT2 3302/4885 |
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | PTGES 2696/4885HTT 3537/4885SIRT2 4042/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | PTGES 2696/4885HTT 3537/4885SIRT2 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.